Abstract
Diabetic kidney disease (DKD) is one of the primary causes of end-stage renal disease (ESRD). Early diagnosis is very important in preventing the development of DKD. Urinary albumin excretion rate (UAER) and glomerular filtration rate (GFR) are widely accepted as criteria for the diagnosis and clinical grading of DKD, and microalbuminuria has been recommended as the first clinical sign of DKD. The natural history of DKD has been divided into three stages: normoalbuminuria, microalbuminuria, and macroalbuminuria. However, this clinical paradigm has been questioned recently, as studies have shown that a portion of diabetes mellitus (DM) patients with normoalbuminuria have progressive renal insufficiency, referred to as normoalbuminuric diabetic kidney disease (NADKD) or nonalbuminuric diabetic nephropathy. Epidemiologic research has demonstrated that normoalbuminuric diabetic kidney disease is common, and the large number of NADKD patients suggests that the traditional paradigm needs to be shifted. Currently, the pathogenesis of NADKD remains unclear, but many clinical studies have identified some clinical and pathological features of NADKD. In addition, the long-term outcomes of NADKD patients remain controversial. In this article, we reviewed the latest studies addressing the pathogenesis, pathology, treatment and prevention of NADKD.
Similar content being viewed by others
References
Xiao L, Wang M, Yang S, Liu F, Sun L. A glimpse of the pathogenetic mechanisms of Wnt/β-catenin signaling in diabetic nephropathy. Biomed Res Int 2013;2013:987064
Kwak SH, Park KS. Genetic studies on diabetic microvascular complications: focusing on genome-wide association studies. Endocrinol Metab (Seoul) 2015; 30(2): 147–158
Xu X, Xiao L, Xiao P, Yang S, Chen G, Liu F, Kanwar YS, Sun L. A glimpse of matrix metalloproteinases in diabetic nephropathy. Curr Med Chem 2014; 21(28): 3244–3260
KDOQI. KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. Am J Kidney Dis 2007; 49(2 Suppl 2): S12–S154
Remuzzi G, Schieppati A, Ruggenenti P. Clinical practice. Nephropathy in patients with type 2 diabetes. N Engl J Med 2002; 346(15): 1145–1151
Tsalamandris C, Allen TJ, Gilbert RE, Sinha A, Panagiotopoulos S, Cooper ME, Jerums G. Progressive decline in renal function in diabetic patients with and without albuminuria. Diabetes 1994; 43 (5): 649–655
MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith TJ, McNeil KJ, Jerums G. Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 2004; 27(1): 195–200
Lacquaniti A, Donato V, Pintaudi B, Di Vieste G, Chirico V, Buemi A, Di Benedetto A, Arena A, Buemi M. “Normoalbuminuric” diabetic nephropathy: tubular damage and NGAL. Acta Diabetol 2013; 50(6): 935–942
Mottl AK, Kwon KS, Mauer M, Mayer-Davis EJ, Hogan SL, Kshirsagar AV. Normoalbuminuric diabetic kidney disease in the U.S. population. J Diabetes Complications 2013; 27(2): 123–127
MacIsaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011; 20(3): 246–257
American Diabetes Association. Standards of medical care in diabetes—2015 abridged for primary care providers. Clin Diabetes 2015; 33(2): 97–111
Zelmanovitz T, Gross JL, Oliveira JR, Paggi A, Tatsch M, Azevedo MJ. The receiver operating characteristics curve in the evaluation of a random urine specimen as a screening test for diabetic nephropathy. Diabetes Care 1997; 20(4): 516–519
Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, Lewis JB. Renal dysfunction in the presence of normoalbuminuria in type 2 diabetes: results from the DEMAND study. Cardiorenal Med 2012; 2(1): 1–10
Kramer CK, Leitão CB, Pinto LC, Silveiro SP, Gross JL, Canani LH. Clinical and laboratory profile of patients with type 2 diabetes with low glomerular filtration rate and normoalbuminuria. Diabetes Care 2007; 30(8): 1998–2000
Bhalla V, Zhao B, Azar KM, Wang EJ, Choi S, Wong EC, Fortmann SP, Palaniappan LP. Racial/ethnic differences in the prevalence of proteinuric and nonproteinuric diabetic kidney disease. Diabetes Care 2013; 36(5): 1215–1221
Rigalleau V, Lasseur C, Raffaitin C, Beauvieux MC, Barthe N, Chauveau P, Combe C, Gin H. Normoalbuminuric renal-insufficient diabetic patients: a lower-risk group. Diabetes Care 2007; 30(8): 2034–2039
Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR; UKPDS Study Group. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55(6): 1832–1839
Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M; Japan Diabetes Clinical Data Management Study Group. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant 2009; 24(4): 1212–1219
Thomas MC, Macisaac RJ, Jerums G, Weekes A, Moran J, Shaw JE, Atkins RC. Nonalbuminuric renal impairment in type 2 diabetic patients and in the general population (national evaluation of the frequency of renal impairment cO-existing with NIDDM [NEFRON] 11). Diabetes Care 2009; 32(8): 1497–1502
Penno G, Solini A, Bonora E, Fondelli C, Orsi E, Zerbini G, Trevisan R, Vedovato M, Gruden G, Cavalot F, Cignarelli M, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Clinical significance of nonalbuminuric renal impairment in type 2 diabetes. J Hypertens 2011; 29(9): 1802–1809
Kramer HJ, Nguyen QD, Curhan G, Hsu CY. Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus. JAMA 2003; 289(24): 3273–3277
New JP, Middleton RJ, Klebe B, Farmer CK, de Lusignan S, Stevens PE, O’Donoghue DJ. Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice. Diabet Med 2007; 24(4): 364–369
Boronat M, García-Cantón C, Quevedo V, Lorenzo DL, López-Ríos L, Batista F, Riaño M, Saavedra P, Checa MD. Non-albuminuric renal disease among subjects with advanced stages of chronic kidney failure related to type 2 diabetes mellitus. Ren Fail 2014; 36(2): 166–170
Penno G, Solini A, Zoppini G, Orsi E, Zerbini G, Trevisan R, Gruden G, Cavalot F, Laviola L, Morano S, Nicolucci A, Pugliese G; Renal Insufficiency And Cardiovascular Events (RIACE) Study Group. Rate and determinants of association between advanced retinopathy and chronic kidney disease in patients with type 2 diabetes: the Renal Insufficiency And Cardiovascular Events (RIACE) Italian multicenter study. Diabetes Care 2012; 35(11): 2317–2323
Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, Zinman B, Lachin J; Epidemiology of Diabetes Interventions and Complications Study Group. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010; 33(7): 1536–1543
Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 2005; 54(10): 2983–2987
Lane PH, Steffes MW, Mauer SM. Glomerular structure in IDDM women with low glomerular filtration rate and normal urinary albumin excretion. Diabetes 1992; 41(5): 581–586
Neugarten J, Acharya A, Silbiger SR. Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 2000; 11(2): 319–329
Porrini E, Ruggenenti P, Mogensen CE, Barlovic DP, Praga M, Cruzado JM, Hojs R, Abbate M, de Vries AP; ERA-EDTA diabesity working group. Non-proteinuric pathways in loss of renal function in patients with type 2 diabetes. Lancet Diabetes Endocrinol 2015; 3(5): 382–391
Diamond-Stanic MK, You YH, Sharma K. Sugar, sex, and TGF-β in diabetic nephropathy. Semin Nephrol 2012; 32(3): 261–268
Ahmed SB, Culleton BF, Tonelli M, Klarenbach SW, Macrae JM, Zhang J, Hemmelgarn BR; Alberta Kidney Disease Network. Oral estrogen therapy in postmenopausal women is associated with loss of kidney function. Kidney Int 2008; 74(3): 370–376
An JH, Cho YM, Yu HG, Jang HC, Park KS, Kim SY, Lee HK. The clinical characteristics of normoalbuminuric renal insufficiency in Korean type 2 diabetic patients: a possible early stage renal complication. J Korean Med Sci 2009; 24(Suppl): S75–S81
Shimizu M, Furuichi K, Yokoyama H, Toyama T, Iwata Y, Sakai N, Kaneko S, Wada T. Kidney lesions in diabetic patients with normoalbuminuric renal insufficiency. Clin Exp Nephrol 2014; 18(2): 305–312
Taniwaki H, Nishizawa Y, Kawagishi T, Ishimura E, Emoto M, Okamura T, Okuno Y, Morii H. Decrease in glomerular filtration rate in Japanese patients with type 2 diabetes is linked to atherosclerosis. Diabetes Care 1998; 21(11): 1848–1855
MacIsaac RJ, Panagiotopoulos S, McNeil KJ, Smith TJ, Tsalamandris C, Hao H, Matthews PG, Thomas MC, Power DA, Jerums G. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease? Diabetes Care 2006; 29(7): 1560–1566
Boeri D, Derchi LE, Martinoli C, Simoni G, Sampietro L, Storace D, Ponte L, Calvi C, Repetto M, Robaudo C, Maiello M. Intrarenal arteriosclerosis and impairment of kidney function in NIDDM subjects. Diabetologia 1998; 41(1): 121–124
Mattock MB, Barnes DJ, Viberti G, Keen H, Burt D, Hughes JM, Fitzgerald AP, Sandhu B, Jackson PG. Microalbuminuria and coronary heart disease in NIDDM: an incidence study. Diabetes 1998; 47(11): 1786–1792
Lam KS, Cheng IK, Janus ED, Pang RW. Cholesterol-lowering therapy may retard the progression of diabetic nephropathy. Diabetologia 1995; 38(5): 604–609
Ekinci EI, Jerums G, Skene A, Crammer P, Power D, Cheong KY, Panagiotopoulos S, McNeil K, Baker ST, Fioretto P, Macisaac RJ. Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function. Diabetes Care 2013; 36(11): 3620–3626
Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G; Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004; 351(19): 1941–1951
Border WA, Yamamoto T, Noble NA. Transforming growth factor β in diabetic nephropathy. Diabetes Metab Rev 1996; 12(4): 309–339
Bader R, Bader H, Grund KE, Mackensen-Haen S, Christ H, Bohle A. Structure and function of the kidney in diabetic glomerulosclerosis. Correlations between morphological and functional parameters. Pathol Res Pract 1980; 167(2-4): 204–216
Lane PH, Steffes MW, Fioretto P, Mauer SM. Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int 1993; 43(3): 661–667
Taft JL, Nolan CJ, Yeung SP, Hewitson TD, Martin FI. Clinical and histological correlations of decline in renal function in diabetic patients with proteinuria. Diabetes 1994; 43(8): 1046–1051
Sun L, Kanwar YS. Relevance of TNF-α in the context of other inflammatory cytokines in the progression of diabetic nephropathy. Kidney Int 2015; 88(4): 662–665
Perkins BA, Krolewski AS. Early nephropathy in type 1 diabetes: the importance of early renal function decline. Curr Opin Nephrol Hypertens 2009; 18(3): 233–240
Navarro JF, Mora-Fernández C. The role of TNF-α in diabetic nephropathy: pathogenic and therapeutic implications. Cytokine Growth Factor Rev 2006; 17(6): 441–450
Schelling JR, Nkemere N, Kopp JB, Cleveland RP. Fas-dependent fratricidal apoptosis is a mechanism of tubular epithelial cell deletion in chronic renal failure. Lab Invest 1998; 78(7): 813–824
Perianayagam MC, Murray SL, Balakrishnan VS, Guo D, King AJ, Pereira BJ, Jaber BL. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure. J Lab Clin Med 2000; 136(4): 320–327
Niewczas MA, Ficociello LH, Johnson AC, Walker W, Rosolowsky ET, Roshan B, Warram JH, Krolewski AS. Serum concentrations of markers of TNFα and Fas-mediated pathways and renal function in nonproteinuric patients with type 1 diabetes. Clin J Am Soc Nephrol 2009; 4(1): 62–70
Tonelli M, Sacks F, Pfeffer M, Jhangri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. Kidney Int 2005; 68(1): 237–245
Bell JH, Herrera AH, Li Y, Walcheck B. Role of ADAM17 in the ectodomain shedding of TNF-α and its receptors by neutrophils and macrophages. J Leukoc Biol 2007; 82(1): 173–176
Onuigbo MA. Syndrome of rapid-onset end-stage renal disease: a new unrecognized pattern of CKD progression to ESRD. Ren Fail 2010; 32(8): 954–958
Ascon M, Ascon DB, Liu M, Cheadle C, Sarkar C, Racusen L, Hassoun HT, Rabb H. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009; 75(5): 526–535
Basile DP, Anderson MD, Sutton TA. Pathophysiology of acute kidney injury. Compr Physiol 2012; 2(2): 1303–1353
Basile DP, Donohoe D, Roethe K, Osborn JL. Renal ischemic injury results in permanent damage to peritubular capillaries and influences long-term function. Am J Physiol Renal Physiol 2001; 281(5): F887–F899
Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012; 82(5): 516–524
Zhao Z, Zhu B, Anderson J, Fu H, Le Narz L. Resource utilization and healthcare costs for acute coronary syndrome patients with and without diabetes mellitus. J Med Econ 2010; 13(4): 748–759
Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004; 351(13): 1296–1305
Waikar SS, Liu KD, Chertow GM. Diagnosis, epidemiology and outcomes of acute kidney injury. Clin J Am Soc Nephrol 2008; 3(3): 844–861
Thakar CV, Christianson A, Himmelfarb J, Leonard AC. Acute kidney injury episodes and chronic kidney disease risk in diabetes mellitus. Clin J Am Soc Nephrol 2011; 6(11): 2567–2572
Onuigbo MA, Agbasi N. Diabetic nephropathy and CKD-analysis of individual patient serum creatinine trajectories: a forgotten diagnostic methodology for diabetic CKD prognostication and prediction. J Clin Med 2015; 4(7): 1348–1368
Araki S, Haneda M, Sugimoto T, Isono M, Isshiki K, Kashiwagi A, Koya D. Polymorphisms of the protein kinase C-β gene (PRKCB1) accelerate kidney disease in type 2 diabetes without overt proteinuria. Diabetes Care 2006; 29(4): 864–868
Shimizu M, Furuichi K, Toyama T, Kitajima S, Hara A, Kitagawa K, Iwata Y, Sakai N, Takamura T, Yoshimura M, Yokoyama H, Kaneko S, Wada T; Kanazawa Study Group for Renal Diseases and Hypertension.Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care 2013; 36(11): 3655–3662
Yagil C, Barak A, Ben-Dor D, Rosenmann E, Bernheim J, Rosner M, Segev Y, Weksler-Zangen S, Raz I, Yagil Y. Nonproteinuric diabetes-associated nephropathy in the Cohen rat model of type 2 diabetes. Diabetes 2005; 54(5): 1487–1496
Levey AS, Cattran D, Friedman A, Miller WG, Sedor J, Tuttle K, Kasiske B, Hostetter T. Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54(2): 205–226
Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M, Cavalot F, Gruden G, Lamacchia O, Laviola L, Orsi E, Pugliese G; Renal Insufficiency Cardiovascular Events (RIACE) Study Group. Independent correlates of urinary albumin excretion within the normoalbuminuric range in patients with type 2 diabetes: The Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicentre Study. Acta Diabetol 2015; 52(5): 971–981
Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, Krolewski AS. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol 2007; 18(4): 1353–1361
De Cosmo S, Lamacchia O, Pacilli A, Fariello S, Pinnelli S, Fontana A, Di Mauro L, Cignarelli M, Trischitta V. Normoalbuminuric renal impairment and all-cause mortality in type 2 diabetes mellitus. Acta Diabetol 2014; 51(4): 687–689
Nielsen SE, Schjoedt KJ, Astrup AS, Tarnow L, Lajer M, Hansen PR, Parving HH, Rossing P. Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM1) in patients with diabetic nephropathy: a cross-sectional study and the effects of lisinopril. Diabet Med 2010; 27(10): 1144–1150
de Carvalho JA, Tatsch E, Hausen BS, Bollick YS, Moretto MB, Duarte T, Duarte MM, Londero SW, Premaor MO, Comim FV, Delanghe JR, Moresco RN. Urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin as indicators of tubular damage in normoalbuminuric patients with type 2 diabetes. Clin Biochem 2016; 49(3): 232–236
Lim SC, Liying DQ, Toy WC, Wong M, Yeoh LY, Tan C, Lau D, Tan C, Subramaniam T, Sum CF. Adipocytokine zinc α2 glycoprotein (ZAG) as a novel urinary biomarker for normoalbuminuric diabetic nephropathy. Diabet Med 2012; 29(7): 945–949
Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, Kaise R, Ishimitsu T, Tanaka Y, Kimura K. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care 2011; 34(3): 691–696
Alter ML, Kretschmer A, Von Websky K, Tsuprykov O, Reichetzeder C, Simon A, Stasch JP, Hocher B. Early urinary and plasma biomarkers for experimental diabetic nephropathy. Clin Lab 2012; 58(7-8): 659–671
National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1–S266
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130(6): 461–470
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41
Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003; 52(4): 1036–1040
Van Buren PN, Toto R. Current update in the management of diabetic nephropathy. Curr Diabetes Rev 2013; 9(1): 62–77
Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345(12): 861–869
Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345(12): 851–860
Satirapoj B, Kaewput W, Supasyndh O, Ruangkanchanasetr P. Effect of sulodexide on urinary biomarkers of kidney injury in normoalbuminuric type 2 diabetes: a randomized controlled trial. J Diabetes Res 2015; 2015:172038
Nielsen SE, Reinhard H, Zdunek D, Hess G, Gutiérrez OM, Wolf M, Parving HH, Jacobsen PK, Rossing P. Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients. Diabetes Res Clin Pract 2012; 97(1): 71–76
Dwyer JP, Lewis JB. Nonproteinuric diabetic nephropathy: when diabetics don’t read the textbook. Med Clin North Am 2013; 97(1): 53–58
Acknowledgments
This study was sponsored by National Natural Science Foundation of China (Nos. 81470960, 81270812, 81570658, 81300600, and 81370832).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Chen, C., Wang, C., Hu, C. et al. Normoalbuminuric diabetic kidney disease. Front. Med. 11, 310–318 (2017). https://doi.org/10.1007/s11684-017-0542-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11684-017-0542-7